FDA seeks investigation of its own Alzheimer’s drug approval
It’s the latest fallout over last month’s approval of Aduhelm, an expensive and unproven therapy from Cambridge drugmaker Biogen that the agency OK’d in June against the advice of its own outside experts.
Support Real Journalism
Subscribe to the Globe for just 99 cents